Oncology Co. Board Hit With Suit Over Product Growth Claims
Executives and directors of radiopharmaceuticals company Lantheus Holdings Inc. have been hit with an investor's derivative suit accusing them of allowing the company to misrepresent the growth potential of its key...To view the full article, register now.
Already a subscriber? Click here to view full article